Screener
Ocular Therapeutix OCUL Q2 2026 earnings
Reported August 3, 2026 · Before market open
Revenue$13.5MBeat by $273.6K
EPS-$0.35Beat by $0.05
Revenue estimate$13.2M
EPS estimate-$0.40
“This approach is designed to support the fastest risk-mitigated path to NDA submission and review. Consistent with the FDA Type C meeting minutes, the AXPAXLI NDA submission will be based on SOL-1 efficacy and safety data, interim safety data from SOL-R and supporting confirmatory evidence, including axitinib's established profile as a VEGFR inhibitor from more than a decade of clinical use since FDA approval for renal cell carcinoma. By pursuing the 505(b)(2) regulatory pathway, we believe the AXPAXLI NDA submission is strongly positioned to benefit from a review timeline up to 60 days shorter than the typical new molecular entity.”
Next report
Nov 3, 2026 (in 2 months)Revenue estimate$14.3M
EPS estimate-$0.36
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Ocular Therapeutix report Q2 2026 earnings?
- Ocular Therapeutix (OCUL) reported Q2 2026 earnings on August 3, 2026 before market open.
- What were Ocular Therapeutix's Q2 2026 revenue and EPS?
- Ocular Therapeutix reported revenue of $13.5M and eps of $-0.35 for Q2 2026.
- Did Ocular Therapeutix beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $13.2M by $273.6K. EPS beat the consensus estimate of $-0.40 by $0.05.
- How did Ocular Therapeutix's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 0.1% from $13.5M a year earlier and eps grew 10.3% from $-0.39.
- Where can I find Ocular Therapeutix's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001104659-26-089443) and the 10-Q periodic report (0001104659-26-089450) directly on SEC EDGAR. The filing index links above go to sec.gov.
